Michael E. Williams - Concepedia

Author

Michael E. Williams

University of Virginia Health System

Also Known As

M E Williams, M. E. Williams, M.E. Williams, Michael E Williams, Michael E. Williams, Williams, Michael E

270

Publications

5.9K

Citations

H-Index

Concepts

All Affiliations

University of Virginia Health System Hackensack University Medical Center Mayo Clinic in Arizona Mayo Clinic University of Wisconsin–Madison

About

Michael E. Williams is an author at University of Virginia Health System specializing in medicine, oncology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	1.4K
2	Health Sciences	3	3	1.2K
3	Engineering	1	1	31
4	Natural Sciences	1	1	31
5	Allergy	1	1	22

Michael E. Williams

Publications

5.8K

Citations

H-Index

Page 1

	Year	Citations
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Peter McLaughlin, A.J. Grillo-López, Brian K. Link, Journal of Clinical Oncology	1998	2.8K
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial S. Vincent Rajkumar, Susanna Jacobus, Natalie S. Callander, The Lancet Oncology Hematological MalignancyMedicineHematologyClinical TrialsMyeloid Neoplasia	2009	930
Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's Lymphoma Katherine Robinson, Michael E. Williams, Richard H. van der Jagt, Journal of Clinical Oncology	2008	352
Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study André Goy, Rajni Sinha, Michael E. Williams, Journal of Clinical Oncology	2013	348
Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study Jonathan W. Friedberg, Philip Cohen, Ling Chen, Journal of Clinical Oncology	2008	298
Single-Agent Monoclonal Antibody Efficacy in Bulky Non-Hodgkin's Lymphoma: Results of a Phase II Trial of Rituximab Thomas A. Davis, Christine A. White, A.J. Grillo-López, Journal of Clinical Oncology ImmunologyImmunotherapyHematological MalignancyOncologyHematology	1999	289
Rituximab Extended Schedule or Re-Treatment Trial for Low–Tumor Burden Follicular Lymphoma: Eastern Cooperative Oncology Group Protocol E4402 Brad S. Kahl, Fangxin Hong, Michael E. Williams, Journal of Clinical Oncology	2014	191
Chromosome 11q13 Amplification in Head and Neck Squamous Cell Carcinoma: Association With Poor Prognosis Scott D. Meredith, P. A. Levine, James A. Burns, Archives of Otolaryngology - Head and Neck Surgery	1995	149
Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network Chan Y. Cheah, Anupkumar George, Eva Giné, Annals of Oncology Prognostic FactorsNeuro-oncologyLymphoid NeoplasiaMantle Cell LymphomaPathology	2013	130
Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study Nathan Fowler, Brad S. Kahl, Peter P. Lee, Journal of Clinical Oncology	2011	108

Page 1